Lawsuit Overview
Within 24 hours after Celgene announced its offer to buy Abraxis Bioscience, Inc for $2.9billion an investor filed a lawsuit in the California Court on behalf of current investors Abraxis Bioscience, Inc. (NASDAQ:ABII) alleging breaches of fiduciary duty by certain members of the Abraxis Bioscience board of directors for selling Abraxis Bioscience too cheaply to Celgene Corp. Abraxis...
You must register (for free) or login to view the entire case.